Post-hoc analysis of ChAdOx1 nCoV-19 vaccine efficacy

Post-hoc analysis of ChAdOx1 nCoV-19 vaccine efficacy against B.1.1.7 variant shows reduced neutralisation activity compared with a non-B.1.1.7 variant in vitro, but supports ongoing use of the vaccine in vaccination programmes given degree of efficacy. Read https://hubs.li/H0KdKSs0

In a linked Comment, Rogier Sanders and Menno de Jong suggest the early findings are encouraging, but additional data are needed to “fully appreciate the potential impact of this and other variants of concern on current and future vaccine efficacy…” Read https://hubs.li/H0KdKPG0

Créditos: Comité científico Covid